Patoloxía Molecular das Doenzas Raras
PatMol-DR
![Foto de Patoloxía Molecular das Doenzas Raras](/img/grupo.png)
![Foto de McMaster University](/img/noimage_org.png)
McMaster University
Hamilton, CanadáPublicacións en colaboración con investigadores/as de McMaster University (5)
2019
-
Management and 1-year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: Results from the prospective garfield-af registry
Journal of the American Heart Association, Vol. 8, Núm. 3
-
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180
2016
-
Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists
British Journal of Haematology, Vol. 174, Núm. 4, pp. 610-623
2013
-
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus
JAMA Internal Medicine, Vol. 173, Núm. 18, pp. 1682-1692
-
Edoxaban versus warfarin in patients with atrial fibrillation
New England Journal of Medicine, Vol. 369, Núm. 22, pp. 2093-2104